Sudarshan Pharma Industries Q2 Results 2026: PAT ₹8 Cr (+101% YoY)
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹217Cr
- +28.5% YoY
- +24.4% QoQ
- Net profit
- ₹8Cr
- +101% YoY
- +38.7% QoQ
- Margin
- 9.49%
- +4 pp YoY
- +0.4 pp QoQ
Top 10 Chemicals & Petrochemicals companies on management guidance
See the sector's top 10 — free with your mobile number.
Sudarshan Pharma Industries Ltd Q2 FY27 key numbers
- Revenue
- Revenue from Operations for September 2026 quarter: ₹391.39 Cr.
As stated in Sudarshan Pharma Industries Ltd's Q2 FY27 investor presentation · published 6 Nov 2026. Reported figures, not investment advice.
Based on Sudarshan Pharma Industries Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for September 2026 quarter: ₹391.39 Cr (Page 41). For the quarter ending September 2026:.
From Sudarshan Pharma Industries Ltd's Q2 FY27 earnings-call transcript · updated 7 Nov 2026.
How did Sudarshan Pharma Industries' revenue grow in the September 2026 quarter?
- Revenue from Operations for September 2026 quarter: ₹391.39 Cr (Page 41)
- Revenue from Operations for September 2025 quarter: ₹314.13 Cr (Page 41)
- Year-on-year growth: Approximately +24.7% (₹391.39 Cr vs ₹314.13 Cr)
- Financial year revenue growth: FY26 ₹703.06 Cr vs FY25 ₹505.05 Cr (+39.2%) as per Page 42.
2 more points from Sudarshan Pharma Industries Ltd's call on revenue
Create a free account to keep reading this call
What happened to Sudarshan Pharma Industries' margins in Q2 FY27?
See what Sudarshan Pharma Industries Ltd said on profitability & margins — free account, 30 seconds.
What capex is Sudarshan Pharma Industries planning?
- Setting up a manufacturing unit for critical APIs currently imported from China (Page 32).
- Nutraceuticals Plant project:
- Project cost: Rs. 2.5 Cr.
- Machinery cost: Rs. 1.15 Cr.
- Capsule and oral liquid manufacturing unit erected at Palghar (2021-2022 milestones, Page 9).
- Acquired capex for Rs. 25.50 Cr. from Srigen Lifesciences Private Limited (2025-2026 milestones, Page 9).
2 more points from Sudarshan Pharma Industries Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Sudarshan Pharma Industries raising money or cutting debt?
See what Sudarshan Pharma Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Sudarshan Pharma Industries' order book?
See what Sudarshan Pharma Industries Ltd said on order book & pipeline — free account, 30 seconds.
Sudarshan Pharma Industries Ltd — Quarterly revenue & net profit
Sudarshan Pharma Industries Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 217 | 169 | +28.5% | 174 | +24.4% |
| Operating profit (EBITDA) | 21 | 9 | +123.6% | 16 | +29.5% |
| Operating margin | 9.49% | 5.45% | +4 pp | 9.12% | +0.4 pp |
| Profit before tax | 11 | 4 | +155.3% | 8 | +44% |
| Net profit (PAT) | 8 | 4 | +101% | 6 | +38.7% |
| EPS (₹) | 0.32 | 0.17 | +88.2% | 0.23 | +39.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Chemicals & Petrochemicals
Continue your research
What Sudarshan Pharma's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sudarshan Pharma Industries Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sudarshan Pharma Industries Ltd Q2 FY27 results?
Sudarshan Pharma Industries reported net profit of ₹8 Cr (+101% YoY) on revenue of ₹217 Cr (+28.5% YoY) in Q2 FY27.
What is Sudarshan Pharma Industries Ltd share price analysis?
Sudarshan Pharma Industries Ltd currently shows a neutral. The stock trades at a P/E of 28.3 with a market cap of ₹822 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sudarshan Pharma Industries Ltd planning capital expenditure?
Setting up a manufacturing unit for critical APIs currently imported from China (Page 32).
Keep Sudarshan Pharma Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
